Sprint Bioscience AB (publ) (STO:SPRINT)

Market Cap	47.48M
Revenue (ttm)	62.38M
Net Income (ttm)	-20.85M
Shares Out	105.52M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	4.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25
Average Volume	317,010
Open	0.4630
Previous Close	0.4500
Day's Range	0.4630 - 0.4630
52-Week Range	0.3600 - 2.2100
Beta	-0.57
RSI	42.21
Earnings Date	Aug 22, 2025

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PETRA01, a drug candidate for the treatment of cancer. In addition, the company focuses on research of products for the treatment of tumor metabolism and ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 38
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SPRINT

Financial Performance

In 2024, Sprint Bioscience AB's revenue was 66.14 million, an increase of 27.97% compared to the previous year's 51.69 million. Losses were -18.28 million, 4072.8% more than in 2023.